Many cases of early prostate cancer are dominated by cells that are slow-growing, often leading to a clinical decision to monitor for progression before initiating treatments that can have adverse side effects.
But some of these cancers might also include a small number of aggressive cells hiding among the indolent ones like wolves in a herd of sheep.
Researchers at Duke Health have identified a molecular signature that can spot these lurking threats.
Publishing online in the journal European Urology, the researchers said the genomic signature they have identified makes it possible to develop a test to identify which men should undergo treatment early in their diagnosis, vs. those who could safely postpone therapy, if needed at all.
“We performed single-cell RNA sequencing analysis of freshly isolated tumour cells from primary, untreated prostate cancers in men as well as advanced cancer cells,” said Jiaoti Huang, M.D., Ph.D., chair of Duke’s Department of Pathology and a senior author of the study.
“We discovered that a small fraction - less than 0.5% - of primary prostate cancer cells possess the genomic features of advanced and aggressive prostate cancer cells that have become resistant to hormonal therapies,” Huang said. “This shows that hormonal therapy resistance can be a feature present in a small number of tumour cells early in the disease process before therapy.”
Huang said the goal now is to develop a clinical assay that identifies the more dangerous cells, which could trigger earlier, aggressive treatment in some patients to avoid disease progression.
Source: Duke University Medical Center
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.